沪公网安备 31011202002810号

关闭

Company strengths

A global Oncology Pharmaceutical Company Founded in China

Committed to Enhancing and Improving Survival of Tumor Patients through Personalized Tumor Immunotherapy

  • 01/Unique Business Structure

    It is one of those pioneers promoting the clinical approval of tumor immunotherapy with the help of precision medicine and combined immunotherapy

    A marketing team covering 4,000 oncologists has been established for companion diagnostics and testing services. The marketing network will see a fivefold increase in the next two years to boost the sales of drugs

  • 02/Potential Global Market

    As a leading tumor precision immune drugs development company in China, it has three global-market-oriented novel drug projects for tumor immunology, two of which are about to launch phase II and phase III key clinical trials worldwide

    It is one of the few novel drug development companies in China that promotes innovative drugs into the later stages of global MRCT clinical trials

  • 03/Strategy of "PD-L1 skeleton" Combination Immunotherapy Pipeline

    The tumor combination immunotherapy strategy for integrating global innovative drug resources centered on anti-PD-L1 antibody boosts multiple combination therapies into global clinical trials. In the next year, 7 combination therapies will enter global clinical trials in multiple indications.

  • 04/Predictable Significant Progress

    Key clinical trial data of the marker-driven PD-L1 antibody guided by precision medicine will be published within 12 months.

    It is expected that two first-line tumor immune drugs, which are being tested in key phase II and phase III clinical trials in China and the United States, will complete NDA submissions for no less than 5 indications in China and the United States in 2019 and 2020, respectively

  • icon

    Stay True to the Mission

    Time is the Mark that the Pioneer Goes Forward, and the Witness that the Striver Builds a Dream

  • icon

    Dare to Innovate

    Make Breakthroughs and Innovate More

  • icon

    Patient First

    Maximize 3DMed’s Value through Patient-centered Preventive Treatment of Disease

向左 向右
    • 3DMed was incorporated in Shanghai

    2010

  • 2011

    • The construction of China's first targeted drug development platform started
    • The first round of venture capital fund raising was completed
    • Master Test was officially launched for precision medication testing
    • The development of Class 1.1 precision anti-tumor drugs was initiated
    • MasterView was released as the precision treatment decision tool for tumors

    2012

  • 2013

    • The world's largest development platform for precision anti-hepatoma drugs was built
    • The second round of venture capital fund raising was completed
    • It became the strategic partner of the Chinese Woman Cancer Prevention Foundation of the All-China Women’s Federation

    2014

  • 2015

    • The third round of venture capital fund raising was completed
    • The fourth round of venture capital fund raising was completed
    • A strategic cooperation agreement was signed with NIH to jointly develop personalized precision drugs for liver cancer
    • The first KN035 monoclonal antibody drug for tumor immunotherapy in China was approved
    • KN035 is approved by the U.S. Food and Drug Administration (FDA) for clinical research in the United States

    2016

  • 2017

    • It was approved as a Shanghai Innovation Company in 2017
    • KN035 was approved for clinical trials by China Food and Drug Administration (CFDA), and was allowed to conduct clinical research in China
    • The first dose of KN035 was given to the first patient in China
    • KN035 was approved by the Pharmaceuticals and Medical Devices Agency (PMDA) for clinical research in Japan
    • Strategic financing of RMB 670,000,000 was acquired
    • A global strategic cooperation agreement was signed with HaiHe Bophirima for innovative drug hh185/3d185
    • KN035 US Phase I clinical data was published, and the late clinical development was initiated

    2018

公司

Wide network of cooperative hospitals: established strategic partnerships
with more than 200 third-grade class-A hospitals in China

Strategic Cooperative Hospitals

  • Liquid biopsy (ctDNA) product line

    Sun Yat-sen University Cancer Center

    (the largest cancer center in southern China for cancer care, education and research)

     

     

  • Gastrointestinal tumor product line

    The Sixth Affiliated Hospital of Sun Yat-Sen University

    (one of the most influential gastrointestinal hospitals in China and a national key clinical hospital)

  • Breast Tumor Product Line

    Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University

    (a large clinical center in southern China for single disease of breast tumor)

  • Gynecological oncology product line

    Chongqing Cancer Hospital

    (chairman of the Committee of Gynecological Oncology, China Anti-Cancer Association)

     

Large Service Groups: Diagnostic product lines brings hope
to more and more patients

Patients benefiting from 3DMed

  • 患者

    3DMed Medical Laboratory served more than 20,000 tumor patients

  • 患者

    About 50% of these patients are recommended with potentially beneficial drugs

患者
合作伙伴
icon

北京市中国医学科学院肿瘤医院

icon

北京大学第二附属医院人民医院

icon

北京大学第一附属医院

icon

复旦大学附属肿瘤医院

icon

上海瑞金医院

icon

上海市中山医院

icon

307医院

icon

中山大学附属第二医院

icon

福建省协和医院

icon

湖南省肿瘤医院

关闭

Novel Drug Development Business

Small Molecule Large Molecule
Project No Mechanism Right PrelND IND Dose Escalation Dose Expansion Registered Trail Difference
KN-035 PD-L1 Global

1st subcutaneous PD-L1 in the world, greatly increased convenience and reduced treatment cost

3D-185 FGFR Global

Targeting Specific signal pathway, potential combination of immunotherapy

3D-011 VEGFR/
PDGFR
Global

Targeting Specific organ, reduce systemic toxicity

  • KN035, the first Chinese original PD-(L)1 drug to achieve dose escalation in China, the United States and Japan, is undergoing two registered clinical trials in China and has started exploratory clinical trials in multiple indications.
  • 3D-011, IND Registration Application in 2019 Q1
关闭

Precision Diagnosis Business

A Management Model of Patient-centered Precision Treatment During the Entire Course of Disease

  • Detection of genetic susceptibility genes of tumors

    • Normal cells

    • Genetic abnormality

    • Beginning of proliferation

    • Breast and ovarian cancer

      BRCA 1/2 gene, risk of breast and ovarian cancer

    • Hereditary colorectal cancer

      17 hereditary colorectal cancer related genes covered

    • Common solid tumor

      44 genes covering BRCAness and HRD-related genes, covering all major hereditary tumor-related genes (recommended by NCCN)

  • Early diagnosis (screening)
    of tumors

    • Precancerous lesion

    • Early tumor

    • Early diagnosis of ovarian cancer

      Ground-breaking exosome detection technology for early diagnosis of ovarian with a sensitivity up to 95%

  • Companion diagnostics for tumor precision medication

    • Cancer confirmed

    • OK Mates series

      The most complete and accurate companion diagnostic product for immunotherapy, fully covering the immunotherapy, targeted therapy, chemotherapy and prognosis

    • Luming series

      Fully excavation of mutagenesis information of tumor patients to assist clinicians in developing personalized treatment plans

    • Dike series

      With the innovative blood ctDNA detection technology, the molecular barcode is added via a self-developed ctDNA sequencing method, and medication guidance, prognosis and efficacy and recurrence monitoring can be performed only by extracting peripheral blood.

  • Detection of genetic susceptibility genes of tumors

    • Proliferation
      and metastasis

    • Dike series

      A fast and flexible blood ctDNA detection method to accurately quantify tumor-derived DNA for rapid efficacy and recurrence monitoring.

关闭

Enterprise team

3DMedicines has an international and professional team of talents with both technical and business thinking.

It covers the professional fields of biology, pharmacy, chemistry, bioinformatics, pharmacology, pathology, FDA new drug approval and clinic, and has extensive experience in product development, marketing, business cooperation, drug development and internationalization.

  • Simon Shung

    Ph.D. Founder & Chairman, co-CEO

    Ph.D in Institute of biochemistry and cell biology, CAS, China.

    Postdoc in UZH,Switzerland.

    Founded 3DMed in 2010, focusing on precision cancer diagnostics and drug development.

    Building up a drug pipeline covering 3 clinical late stage compounds and 1 preclinical clinical candidates.

  • John Gong

    M.D. Ph.D. CEO

    10 years as a US FDA reviewer, familiar with new drug development and international regulations

    Former VP of BeiGene, a leading oncology biopharmaceutical company in China

    Former CTO of JOINN Lab, a leading CRO in China

    Former CEO of BL Pharmaceuticals, Beijing, a prodrug platform company in China

    Ph.D. in Toxicology from New York University

    M.D. from Beijing Medical University

  • Liang Zhang

    EMBA EVP & CHO

    Over 10 years working experience in multinational and domestic companies, Rich experiences inorganization and Culture transformation

    Former VP and Chief HR Officer of CIFI Group (00884.HK)

    Former Chief HR Officer of Kyuan pharmaceutical Inc. of SPH Group

    Former CEO Assistant and HR director of Tasly Group(600535), former HR manager of Motorola(China)

    M.B.A. from CEIBS

  • Simon Xu

    Ph.D.CFA,CFO

    13 years work experience in Life Science research, and investment management in hedge fund/private equity/fund of funds, focusing on the US and Greater China healthcare markets;

    Former Executive Director of China Minsheng Investment Group, invested and managed a global healthcare portfolio of over 250 million USD and sat on boards of directors of several portfolio companies;

    Former Executive Director of China Minsheng Investment Group, invested and managed a global healthcare portfolio of over 250 million USD and sat on boards of directors of several portfolio companies;

    Former Founding Member of BioTechnique, a cytotoxic fill-finish CMO in the US, acquired by LSNE;

    Ph.D. in Genetic, Molecular and Cellular Biology from University of Southern California, CFA Charterholder, HK SFC Type 4 License holder, qualified to conduct private equity investment in China (AMAC)

  • David Liu

    MD, Ph.D.CMO,

    Engaged in research and development of oncology drugs for nearly 20 years with extensive training in both basic science and clinical medicine; Experienced in global clinical development of biologics and small molecules in both solid and blood malignancies.

    Former Executive Medical Director at Celgene USA who led a successful global submission program in the capacity of Global Lead physician; Former Group Medical Director at BMS who played leadership roles in clinical development of ipilimumab, nivolumab, brivanib, and ixabepilone.

    Authored over 20 peer reviewed clinical and basic research articles in prestigious journals including NEJM, Lancet Oncology, JCO, and PNAS; Inventor of over 10 patents.

    Obtained medical degree from Peking University Health Science Center, Master’s degree from the University of Toledo, and PhD from MIT.

  • Jeffrey Lin

    Ph.D. Sr.Director

    Leads 3DMed bio-marker discovery

    Former senior scientist of GSK, responsible for drug screening assay, with rich research experience in epigenetics and leukemia

    Ph.D. in Biochemistry and Molecular Biology from Chinese Academy of Sciences (CAS), Post-Doc from the Chinese Academy of Sciences Institute of Health

  • Meng Fu

    M.D. MBA, VP of Clinical Operation

    Over 15 years' industry experience in clinical operation across AsiaPac, North America, South America, Europe and Australia

    Former General Manager of Gleneagles CRC (China) Pte. Ltd. in China

    Former Global Clinical Operation Team Lead at GE Healthcare in US

    Former Global Project Lead at Syneos Health in US

    Former Clinical operation and Development Director at Pharmacyclics in US

    Former Senior Global Program Lead at Medimmune in US

    MBA from Ohio University, MSc from The University of Sheffield, M.D. from Jilin University, Norman Bethune Medical School

  • LeAnn Li

    M.D., Ph.D. Senior Clinical Operation Director

    15 years working experience in global clinical research and global regulatory affairs

    5 years working experience in clinical practice.

    Former Director of international R&D center of Tasly Group (600535)

    M.D. from HeBei Medical University, Master from Oklahoma State University, Ph.D. from Tianjin University

  • Walt Cao

    Ph.D. RAC, Head, Clinical Pharmacology&Pharmacometrics

    16 years work experience in new drug design, translational sciences, clinical research and development.

    Former US FDA senior clinical pharmacology reviewer and biosimilar lead for oncology drug。 Primarily reviewed and provided regulatory advice for clinical pharmacology & pharmacometrics related clinical trial design & optimization, safety and efficacy, marketing application and post-marketing life-cycle management for oncology drug in US FDA.

    Former Senior Scientist in Boehringer Ingelheim and Abbott /AbbVie;

    Ph.D. in Pharmaceutics from the Ohio State University (2007). Active US Regulatory Affairs Certificate (RAC) holder (2018-2020)

  • Haolan Lu

    Ph.D.Senior Biostatistics Director

    Over 14 years of oncology drug development experience with a proven track of success in immuno-oncology drugs global registration and approvals including two immuno-oncology pioneering drugs: Opdivo (nivolumab) and Yervoy (ipilimumab).

    Former non-small cell lung cancer indication statistical lead of Bristol-Myers Squibb Company, led registration global approvals for Opdivo in the second and third line treatment of NSCLC;

    Ph.D. in Biostatistics from University of Minnesota

  • Caifu Chen

    Ph.D. CTO IVD

    20 years of broad biotech R&D experiences in developing cutting-edge qPCR, CE, dPCR & NGS products for RUO, LDT & Dx

    Passionate R&D leader at multiple companies & countries

    Vice President of Genetic Applications R&D at Thermo Fisher in 2012 - 2014

    Vice President of Molecular Biology R&D in Pall Corporation in 2010 - 2012

    Sr. Director and Scientific Fellow at Applied Biosystems in 1998 - 2010

    Expert qPCR and NGS product developer

    Developed TaqMan MicroRNA Assays, AmpliSeq, Target Capture NGS Kits, and many other TaqMan Assays for RUO, LDT and Dx applications

    Achieving >$800M new product revenues

    Successful collaborator with hundreds of academic institutes and biotech companies in cancer, miRNAs, stem cells, CNVs & single cell analysis

    Productive author of 55 peer-reviewed papers, 8 book chapters, and holder of 36 patents and patent publications

    Molecular geneticist trained at Harvard Medical School in 1996-1998 and University of Missouri in 1993-1996

  • Fugen Li

    Ph.D.,VP, Precision Medicine R&D

    Senior expert in bioinformatics, genomics and bio-marker research

    Former senior bioinformatics scientist at Dana-Farber Cancer Institute in Boston, former CTO of Ibioinform in Boston, former senior scientist at MIT and Sanofi-Aventis

    Ph.D. in Molecular Biology from Oregon State University

  • Hank Yang

    MBA,VP,Data and Information System

    20 years of experience in software system architecture and intelligence algorithm application

    Working experience in Computing Center of Chinese Academy of Sciences, MCI Communications (US) and SAS( a leading company in analytics)

    Former CTO of a software company

    Double Master degree in Mathematics and Computer Science

  • Kangning Chen

    Sales VP of Precision Diagnosis

    18 years' experience in sales management such as generic drug and special medicine

    Worked as a respiratory physician in the Jiangsu Province Hospital after graduation and then joined Xian-Janssen, and promoted to director of One China OTC Business Division

    Graduated from Clinical Medicine, Nanjing Medical University and EMBA of CEIBS

  • Steven Cai

    Strategy Marketing, VP

    2 years experience as a clinician, 20 years experience in sales and marketing of pharmaceuticalcompany

    Held various positions in Xian-Janssen, including marketing director, strategic marketing director,national sales manager

    Bachelor in clinical medicine of Military Medical University, Zhongshan University EMBA

中文